Chronic rhinosinusitis (CRS) is among the most prevalent chronic medical conditions globally. A survey of Canadian households reported the prevalence of CRS to be 5%. CRS is a clinical syndrome defined by persistent symptomatic inflammation of the mucosa in the nasal cavities and sinuses. A common subtype of CRS is CRS with nasal polyps (CRSwNP), which is identified through endoscopy or imaging
Can benign vascular anomalies transform into highly malignant angiosarcoma (AS), and is a more aggressive biopsy/surgical approach warranted in certain cases of these anomalies?
Nasodine, an over-the-counter preparation, shows effective antibiofilm agent that is highly active against biofilms and holds promise for the management of sinonasal biofilms in CRS.
Patients with CRS are likely not inherently more vulnerable to COVID-19 infection at a rate above that of the general population.
Minority demographic groups are significantly underrepresented in chronic rhinosinusitis (CRS) clilnical trials.
A look at the characteristics associated with avoidance of daily activities in patients with chronic rhinosinusitis.
Although acupuncture is used to treat a variety of medical conditions, there is insufficient evidence to support its use in chronic rhinosinusitis.
Preoperatively administered GCS improved olfaction in CRS patients with nasal polyps is comparable to surgery, and changes in steroids predicted olfactory outcome postoperatively.
Statin use is associated with decreased rates of chronic rhinosinusitis (CRS) based on a nationally representative sample of outpatient visits in the United States.
Eosinophil-derived SEMA4D aggravates ECRS, and serum SEMA4D levels reflect disease severity.